Levetiracetam Injection
Product Images NDC 42571-331

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 42571-331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (Levitiracetamcartonlabel)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection by Micro Labs Limited. The carton contains 10 single-dose vials of 5 mL each. The label states the product is for intravenous use only and must be diluted prior to administration. Manufacturer addresses in India and the USA are listed along with storage instructions.*

FDA Label Image

Fig 1 (Levitiracetamfigure1)

Bar chart depicting the percentage of patients in three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Fig 2 (Levitiracetamfigure2)

A bar graph depicting the percentage of patients for three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. Percentages are approximately 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with patient counts indicated below each group (N=111, N=106, N=105 respectively).*

FDA Label Image

Fig 3 (Levitiracetamfigure3)

A bar chart comparing the percentage of patients in two groups: Placebo (N=104) with 14.4%, and Levetiracetam 3000 mg/day (N=108) with 39.4%. The vertical axis represents the percentage of patients.*

FDA Label Image

Fig 4 (Levitiracetamfigure4)

A bar graph comparing the percentage of patients responding in two groups: Placebo (N=97) at 19.6% and Levetiracetam (N=101) at 44.6%. The y-axis represents the percentage of patients from 0% to 45%, showing a higher response rate for Levetiracetam than Placebo.*

FDA Label Image

Fig 5 (Levitiracetamfigure5)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents percent of patients from 0% to 45%. The placebo group (N=51) shows 19.6%, while the Levetiracetam group (N=58) shows 43.1%.*

FDA Label Image

Fig 6 (Levitiracetamfigure6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients, ranging from 0% to 100%. An asterisk marks the Levetiracetam bar.*

FDA Label Image

Label (Levitiracetamlabel)

Label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) by Micro Labs Limited. The vial is a 5 mL single-dose for intravenous use only, with instructions to dilute prior to administration. The label includes storage instructions, barcode, NDC 42571-331-92, and a note indicating Rx only.*

FDA Label Image

Structure (Levitiracetamstrc)

Chemical structure of levetiracetam, depicting a pyrrolidone ring bonded to an ethyl group and an amide group, representing the molecular arrangement of the active ingredient in levetiracetam injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.